JAMA Network JAMA Cardiology : From the JAMA Network: From ESC: Remote Monitoring for Atrial Fibrillation, Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction, and more
Sep 16, 2025
Join Gregory Curfman, JAMA Executive Editor, and Robert O. Bonow, JAMA Cardiology Editor, as they delve into groundbreaking research from the European Society of Cardiology Congress. They discuss the rise of remote monitoring for detecting asymptomatic atrial fibrillation, the benefits of semaglutide and tirzepatide for heart failure, and findings that show improved outcomes from complete revascularization in myocardial infarction. They also highlight important vaccination insights and the ongoing challenges of women’s participation in cardiovascular research.
AI Snips
Chapters
Transcript
Episode notes
Patch Screening Modestly Ups AF Detection
- Two-week ECG patch screening modestly increased detection of asymptomatic AF but the absolute difference was small.
- AMALPHE found no reduction in strokes over 2.5 years, limiting clinical benefit of this approach.
Consider Stopping Anticoagulants After Documented AF Absence
- If atrial fibrillation is definitively absent for a year after successful catheter ablation, clinicians may consider stopping anticoagulation.
- Ensure rigorous rhythm documentation because recurrent AF still carries thromboembolic risk.
Pump Benefit Concentrated In Very Low Systolic BP
- Microaxial flow pump benefit in infarct-related cardiogenic shock appears concentrated in patients with very low systolic BP.
- Post hoc analysis suggested major mortality reduction when systolic BP ≤ ~82 mm Hg at randomization.